Cenoté Pharma
Cenoté Pharma is a private pharmaceutical company specialising in the manufacture and development of medicines for rare metabolic disorders.
The British pharmaceutical company was established in 2015 and has now set up its German subsidiary to make developments and improvements of existing medicines accessible to patients in Europe.
The committed owners invest in the continuous improvement of medicines for children.
“Holy water that brings life”
In Maya culture, a “Cenote” is revered as a “Sacred Oasis”.
When the limestone ceilings (sinkholes) of marine-near cavities collapse, open caves are formed. Up to 6,000 caves have been mapped with depths of up to 150m.
As there were no large rivers in Mexico, water supply was critical.
The MAYA saw the “Cenotes” as a gift from the gods. For they often form the only reliable sources of water during the dry season, and were thus revered as “HOLY WATER” when all sources of life-sustaining water are exhausted. They were considered the seat of the gods.
About Cenoté
As a patient-focused pharmaceutical company, we care for our patients with rare metabolic disorders, continuously improving our medicines.
In incremental innovations, we free medicines from alcohol, sugar, and parabens, which for many manufacturers during the development phase were the preferred means to maintain product stability throughout their lifespan.
However, we firmly believe that these special children deserve more care. And no one can seriously argue that medicines with sugar, pharmaceutical excipients, and dissolved alcohol can harm a sick newborn.
With the high manufacturing expertise of our chosen manufacturers, we constantly work on improvements and innovative active ingredients to relieve the children’s metabolism and to reduce the pharmaceutical active ingredient as much as pharmaceutically possible.
Our priority is to help these needy patients lead a longer and healthier life. Cenote Pharma is committed to developing life-saving drugs that enhance the lives of these patients.
To us, that’s sustainability.
Our Goals
Early Access
Increasing Awareness
To increase the awareness and availability of our life-saving therapeutic developments, and to introduce additional new treatments for patients with rare metabolic diseases.
UK Location
To establish the United Kingdom as the leading distribution hub, expanding our reach across all European Union member states and strengthening our presence in the European market.
CO2 Reduction
To reduce CO2 emissions through the establishment of key regional and corporate partnerships in the Mecklenburg-Western Pomerania area.
Contact
Cenoté Pharma Ltd
Elizabeth House, 13-19 London Road
Newbury, Berkshire RG14 1JL
United Kingdom
Tel: +44 (0)7856 636602
Internet: www.cenotepharma.co.uk
email: keith.williams(at)cenotepharma.com